AX-2026-042130
ARA-290 · 2 mg declared · Guangzhou JEEP Biotechnology Co., Ltd. · lot JEEP-2601-K8319
- Report ID
- AX-2026-042130
- Compound
- ARA-290
- Compound class
- Tissue-repair and immunomodulatory peptides
- Supplier
- JEEP — Guangzhou JEEP Biotechnology Co., Ltd.
- Batch / lot
- JEEP-2601-K8319
- Declared label claim
- 2mg
- Laboratory
- Janoshik Analytical
- Assay date
- 17 Apr 2026
- Submitted
- 28 Apr 2026
- Quarter
- 2026-Q2
- Submitter
- d.karlsen
- Sample provenance
- Buyer-sourced
Results
Measured against the index acceptance specification for the tissue-repair and immunomodulatory peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 30 min gradient, 214 nm | 99.24 | % area | ≥ 98.0 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 0.76 | % area | ≤ 2.0 | PASS |
| Largest single impurity | RP-HPLC — des-Gln truncate (−128 Da) | 0.39 | % area | ≤ 1.00 | PASS |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 1189.6096 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, high resolution (ESI-TOF/QTOF) | 1189.6025 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | -6.0 | ppm | ± 15 | PASS |
| Total peptide content | by difference from the gravimetric mass balance | 90.05 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 89.37 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 2.07 | mg | 2 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 1.850 | mg | 2 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 92.5 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 4.65 | % | ≤ 10.0 | PASS |
| Counter-ion (acetate) | anion-exchange ion chromatography | 4.43 | % | ≤ 12.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.87 | % | — | NOT TESTED |
| Endotoxin | not ordered on this submission | not determined | — | ≤ 5.0 | NOT TESTED |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | White lyophilised cake, intact | — | white to off-white intact cake | PASS |
| Reconstitution clarity | reconstituted per submitter procedure | Clear after 90 s gentle swirling, no particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 4.73 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 30 min gradient | 8.76 | min | 8.72 ± 0.25 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 0.94 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 67,287 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs [D-Ser]-diastereomer | 0.87 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | ARA-290 — main peak | 8.76 | 4,823,372 | 99.24 | — |
| 2 | des-Gln truncate (−128 Da) | 8.46 | 18,955 | 0.39 | -128.059 |
| 3 | [D-Ser]-diastereomer | 8.64 | 9,721 | 0.20 | 0.000 |
| 4 | deamidated (+1 Da) | 8.54 | 4,860 | 0.10 | +0.984 |
| 5 | acetyl adduct (+42 Da) | 9.16 | 3,402 | 0.07 | +42.011 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 1189.6096 Da, computed from C50H83N15O18. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 3+ | 397.5438 | 397.5414 | -0.0024 | 8.0 |
| 2+ | 595.8121 | 595.8085 | -0.0036 | 57.5 |
| 1+ | 1190.6169 | 1190.6098 | -0.0071 | 100.0 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 4.65 |
| Counter-ion (acetate) | ion chromatography | 4.43 |
| Residual solvent + inorganic residue | estimated | 0.87 |
| Total peptide content | by difference | 90.05 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.21 | 99.24 | divergence -0.03 pp vs batch median |
| Total impurities (% area) | not stated | 0.76 | |
| Largest single impurity (% area) | not stated | 0.39 | |
| Water (%) | 2.8 | 4.65 | |
| Counter-ion (%) | 3.3 | 4.43 | |
| Peptide content (%w/w) | 93.3 | 90.05 | |
| Endotoxin (EU/mg) | not stated | not determined | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Buyer-sourced
- Evidentiary weight
- Strongest available evidence in this index.
- Chain of custody
- Retail purchase → submitter (ambient, 24 d) → laboratory (courier, cold pack, 2 d) → assay.
- Assay date
- 17 Apr 2026
- Submitted to the index
- 28 Apr 2026
- Laboratory
- Janoshik Analytical, Ostrava, Czechia
- Method basis
- 30 min gradient · high-resolution MS
- Verification status
- VERIFIED
Annotations
No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.
Related records
Same batch — lot JEEP-2601-K8319 n=3
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042129 | JEEP-2601-K8319 | PeptideMeter | 2026-Q2 | 99.55 | 4.70 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042131 | JEEP-2601-K8319 | PeptideMeter | 2026-Q2 | 99.21 | 4.64 | 89.7 | Buyer-sourced | 1 | MARGINAL |
Cross-sections
- All ARA-290 records n=91
- All JEEP records n=230
- All Janoshik records n=2989
- All 2026-Q2 records n=1126
- ARA-290 by supplier
- ARA-290 impurity profile
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041767 | ASY | ASY-{CAT}-1521 | Janoshik | 2026-Q3 | 99.66 | 4.42 | 103.7 | Buyer-sourced | 0 | PASS |
| AX-2026-043222 | SGN | SGN-2605-X9069 | PeptideMeter | 2026-Q2 | 98.32 | 7.36 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041907 | SinoPep | SNP-2605-G4075 | Janoshik | 2026-Q2 | 99.20 | 5.75 | — | Buyer-sourced | 0 | PASS |
| AX-2026-043227 | SGN | SGN-2605-X9069 | PeptideMeter | 2026-Q2 | 98.38 | 7.21 | 95.6 | Buyer-sourced | 0 | PASS |
| AX-2026-041862 | GSP | GSP-2605-K3362 | Janoshik | 2026-Q2 | 99.34 | 3.32 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041906 | SinoPep | SNP-2605-G4075 | Medutest | 2026-Q2 | 98.94 | 5.28 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042346 | Homopeptide | HOMO-2601-T3123 | PeptideMeter | 2026-Q2 | 99.70 | 3.47 | — | Buyer-sourced | 0 | PASS |
| AX-2026-043229 | SGN | SGN-2605-X9069 | Janoshik | 2026-Q2 | 98.21 | 7.43 | — | Buyer-sourced | 0 | PASS |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042177 | Hexarelin | JEEP-2608-Y9547 | Janoshik | 2026-Q3 | 99.90 | 3.42 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042162 | Semaglutide | JEEP-2607-X9091 | Janoshik | 2026-Q3 | 98.98 | 3.46 | — | Laboratory-retained | 1 | MARGINAL |
| AX-2026-042127 | TB-500 | JEEP-2602-V8614 | Medutest | 2026-Q3 | 99.68 | 3.55 | — | Buyer-sourced | 1 | FAIL |
| AX-2026-042123 | TB-500 | JEEP-2602-V8614 | PeptideMeter | 2026-Q3 | 99.93 | 3.80 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042124 | TB-500 | JEEP-2602-V8614 | PeptideMeter | 2026-Q3 | 99.91 | 3.37 | 104.9 | Buyer-sourced | 0 | PASS |
| AX-2026-042178 | Hexarelin | JEEP-2608-Y9547 | VendorInvestigate | 2026-Q3 | 99.68 | 4.03 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042163 | Semaglutide | JEEP-2607-X9091 | Nordanalyt | 2026-Q3 | 99.46 | 4.52 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042122 | TB-500 | JEEP-2602-V8614 | PeptideMeter | 2026-Q3 | 99.60 | 3.58 | 97.0 | Buyer-sourced | 0 | PASS |